We selected the model of bleomycin, intra-tracheally delivered, because it is the best characterized murine model in use today for lung fibrosis and, nowadays, there are no approved drugs that counteract the pathological mechanism of this disease, apart some potential treatments targeting the TGF-β pathway, pirfenidone, and the tyrosine kinase inhibitor, nintedanib [32,33,34]. This evidence concerns the gene TGFB1 and pulmonary fibrosis.